Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CNC · Q1 2026 Earnings

Centene Corporation

Reported April 28, 2026

30-second summary

Centene delivered Q1 FY2026 adjusted EPS of $3.37 with consolidated HBR of 87.3% — 360bps inside the FY guide of 90.9–91.7% — and lifted the FY2026 adjusted EPS floor by $0.40 to greater than $3.40 alongside a $1B revenue raise. Medicaid HBR of 93.1% improved 50bps YoY and came in ahead of management's internal Q1 projection, validating the margin-recovery thesis on the first read. The setup has flipped: the question is no longer whether the HBR snapback is achievable but how much upside management is sandbagging into "a prudent outlook for the balance of 2026."

Headline numbers

EPS

Q1 FY2026

$3.37

Revenue

Q1 FY2026

$49.94B

+7.1% YoY

Operating margin

Q1 FY2026

3.7%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$49.94B	+7.1%	$49.73B	+0.4%
EPS	$3.37	—	$-1.19	+383.2%
Operating margin	3.7%	—	-3.5%	+724bps

Guidance

UnitedHealth raised full-year 2026 adjusted EPS guidance to greater than $3.40 (from $3.00+) and increased revenue guidance by $1.0B to $171-175B premium and service revenues, driven by strong Q1 execution and operational improvements.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Investment and other income	FY2026	$1.45 billion	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted diluted EPS	FY2026	greater than $3.00	greater than $3.40	+$0.40 above prior floor	Raised
Premium and service revenues	FY2026	$170.0 billion to $174.0 billion	$171.0 billion to $175.0 billion	+$1.0 billion at both ends	Raised
Total revenues	FY2026	$186.5 billion to $190.5 billion	$187.5 billion to $191.5 billion	+$1.0 billion at both ends	Raised
GAAP diluted EPS	FY2026	greater than $1.98	greater than $2.37	+$0.39 above prior floor	Raised
SG&A expense ratio	FY2026	7.1% to 7.7%	7.0% to 7.6%	-0.1 percentage points at both ends	Lowered
Effective tax rate	FY2026	27.0% to 28.0%	Withdrawn — no replacement	—	Withdrawn
Adjusted effective tax rate	FY2026	26.0% to 27.0%	Withdrawn — no replacement	—	Withdrawn
Diluted shares outstanding	FY2026	495.6 million to 498.6 million	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Health Benefits Ratio (HBR) (90.9% to 91.7%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Medicaid	$23.596B	+6.0%
Commercial	$9.556B	-6.0%
Medicare	$10.326B	+18.0%
Other	$1.177B	-8.0%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Health Benefits Ratio (HBR)	87.3%
Medicaid HBR	93.1%
Medicare HBR	84.9%
Commercial HBR	75.3%
SG&A Expense Ratio	7.6%
Total At-Risk Membership	26,272,900
Days in Claims Payable	48 days
Operating Cash Flow	$4.4 billion

Management tone

This quarter the CEO articulated a forward Medicaid HBR commitment: "I would be disappointed if we didn't beat 93.7 given where we stand today. I will reiterate that I will be disappointed if that's all we can do." That is a public sandbag of the consolidated guide, anchored in tangible operating levers (network optimization, scaled clinical programs, fraud/waste/abuse) rather than rate-cycle mechanics. The shift signals management believes the margin floor is structurally higher than what is currently embedded.

The Marketplace narrative is being reframed around risk adjustment economics. Management characterized adverse selection in this market as potentially a strategy: "often it can actually be a profitable strategy to care for sicker members in this market…because as you know, the risk adjustment mechanism is specifically designed to counteract adverse selection." The phrase "wraps around our original 4 percent target margin… and, frankly, higher than that at the top end" signals marketplace 2026 margin upside relative to the prudent ~3% pre-tax margin currently embedded in guidance.

Visibility itself has become a competitive advantage in management's framing. Following last year's marketplace volatility, the company invested in industry data-sharing infrastructure; this quarter management characterised that work as paying off: "As a result of that collaboration, the industry has more visibility than it has ever had at this time of the year about overall market dynamics… we are pleased to see that the market overall behaved in line to slightly favorable to our expectations." Management is signalling that the prior forecasting gap is now structurally addressed.

The ABA narrative has matured from acute cost driver to managed-risk category. Management reports "stabilizing year-over-year ABA trends that we believe are a direct result of the actions we have taken… we continue to strengthen our identification of outlier providers who exhibit suspect or fraudulent billing patterns." The fraud-prevention framing positions ABA stabilization as a durable operating outcome rather than a trend tailwind.

Yet management explicitly chose not to flow Q1 strength fully into the guide: "we are taking a prudent outlook for the balance of 2026 as we continue to gain visibility into key factors." With Q1 FY2026 adjusted EPS of $3.37 already nearly clearing the FY floor of >$3.40, the conservatism is doing more work than the raise. Drew explicitly noted current guidance embeds a Marketplace pre-tax margin "around 3% for now, compared to our original forecast of approximately 4%" — leaving the full risk-adjustment offset as upside to be confirmed by the June Wakely data.

Recurring themes management leaned on this quarter:

Fundamental operational improvements driving margin recovery across MedicaidFraud, waste, and abuse reduction and payment integrity initiatives yielding resultsRisk adjustment mechanism creating profitable opportunity in marketplace despite adverse selectionMulti-year trend management program maturing and scaling across the portfolioState partnerships becoming more sophisticated and constructive on benefit design and program changesMedicare Advantage and PDP positioned for break-even achievement in 2027

Risks management surfaced:

Behavioral health trend remains elevated and is the largest driver of Medicaid cost trendMarketplace silver tier utilization higher than originally forecast, though partially offset by risk adjustmentPart D specialty pharmacy trends remain historically high in non-low-income population post-IRAWork requirements implementation may cause acuity shifts in Medicaid population in 2027-2028Court cases around marketplace program integrity measures may impact 2027 enrollment and risk pool

Answers to last quarter's watch list

Q1 FY2026 Medicaid HBR vs the 90.9–91.7% FY consolidated guide — Consolidated HBR landed at 87.3%, 360bps inside the FY guide, with Medicaid specifically at 93.1% (50bps better YoY) and ahead of management's internal Q1 projection. Margin recovery is overshooting at the consolidated level.

Resolved positively

Marketplace pre-tax margin progression / commercial HBR — Commercial HBR printed 75.3%, essentially flat YoY (+30bps vs 75.0%), described by management as "slightly above expectations." Marketplace pre-tax was in line with expectations as SG&A favorability offset the higher HBR. Management embedded a ~3% pre-tax margin in current guidance versus the ~4% original target, leaving risk-adjustment upside. Status: In progress

Medicare Advantage PDR position — No PDR reintroduction signaled in the Q1 FY2026 print, and Medicare HBR improved 140bps YoY to 84.9%. Management framed Medicare Advantage and PDP as positioned for break-even achievement in 2027.

Resolved positively

NSA litigation escalation — Not addressed in the Q1 FY2026 disclosure.

Continue monitoring

Buyback cadence against 495.6–498.6M share guide — Share count guidance was reaffirmed at 495.6–498.6M. Q1 diluted share count of 495.6M sits at the low end. Status: On track

What to watch into next quarter

Whether the consolidated HBR FY guide of 90.9–91.7% gets lowered alongside Q2 results — Q1 FY2026 printed 87.3%, 360bps inside the range, and management explicitly reaffirmed the FY range rather than tightening it. If Q2 prints anywhere near 89%, the FY range becomes untenable as upper bound and the next raise candidate is the HBR guide itself

Medicaid HBR trajectory toward the CEO's "beat 93.7%" anchor — Q1 FY2026 at 93.1% sets up Q2/Q3 as the test of whether the internal cushion holds or expands. Management explicitly suggested 15–20bps of outperformance vs 93.7% leans positive

June Wakely data and Marketplace risk adjustment receivable — management noted current guidance does not reflect the full risk adjustment offset suggested by current data; the June weekly data is the key gating item for a further marketplace margin uplift

PDP HBR sloping — Drew flagged that PDP-driven sloping should push consolidated HBR higher through the year and pull DCP down a day or two; watch whether Q2 prints validate that mechanical pattern

Risk adjustment receivable disclosure — quantification of the marketplace risk adjustment receivable in Q2 would convert an off-balance-sheet tailwind into a guide raise

Sources

Centene Q1 FY2026 press release, April 28, 2026 (SEC filing)
Centene Q1 FY2026 earnings call (prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.